Novo Nordisk Unveils Wegovy Subscription Service to Counter Competition, Drive Adherence

Novo Nordisk has launched a new multi-month subscription plan for its popular GLP-1 weight loss drug, Wegovy, a strategic move designed to address cost uncertainty and improve patient adherence among self-pay individuals. This initiative, which offers predictable and lower monthly pricing, has already provided a notable boost to Novo Nordisk (NVO) stock, which had been trading near four-year lows.

The subscription service is a calculated effort by Novo Nordisk to attract a larger segment of cash-paying customers and reclaim market share in the rapidly expanding GLP-1 market. The company faces significant competition from Eli Lilly's Zepbound, another injectable GLP-1 drug, as well as from various compounded versions of its own medications, which often offer lower prices but lack regulatory oversight. High discontinuation rates due to cost concerns have also prompted this new approach.

Under the new plan, self-pay patients can access Wegovy injections at reduced rates: $329 per month for a three-month subscription, $299 per month for six months, and $249 per month for a 12-month commitment, potentially saving up to $1,200 annually. A pill version of Wegovy is also available via subscription, priced at $289/month (3-month), $269/month (6-month), and $249/month (12-month), offering annual savings of up to $600. In comparison, Eli Lilly's Zepbound injectable drug currently carries cash prices ranging from $299 to $499 per month, underscoring Novo Nordisk's aggressive pricing strategy to remain competitive.